Ariad Pharmaceuticals Inc fka ARIA

[DonShimoda]

Based on the ASCO abstracts, AP534 appears to be far more effective than bosutinib. In CP pts who have failed 2 tki's(imatinib and dasatinib), bosutinib achieved a 42% MCyR.

In the data released today, AP534 achieved a 48% MCyR BUT the Ariad trial included pts in both the advanced and blast phase's of the disease while the bosutinib trial only included pts in the chronic phase. Bottomline - AP534 achieved a higher MCyR than bosutinib in a sicker patient population.

http://abstract.asco.org/AbstView_74_52695.html